Ovarian Cancer | Specialty

The OncLive Ovarian Cancer condition center page is a comprehensive resource for clinical news and expert insights on ovarian cancer and evolving treatment approaches, including PARP inhibitors, antibody-drug conjugates, chemotherapy and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in ovarian cancer.

Emerging Agents for HER2+ mBC: Targeted Therapeutics

January 11th 2020

Emerging Agents for HER2+ mBC: HER2CLIMB and SOPHIA Trials

January 11th 2020

Evolving Role of Trastuzumab Deruxtecan in HER2+/HER2-Low mBC

January 11th 2020

HER2+ mBC: Addressing ILD in the DESTINY-Breast01 Study

January 11th 2020

HER2+ mBC: Study Design and Results of DESTINY-Breast01

January 11th 2020

HER2+ Breast Cancer: Evolution of Antibody-Drug Conjugates

January 11th 2020

Unmet Needs in the Management of HER2+ mBC

January 11th 2020

Treatment Strategies for Relapsed/Refractory HER2+ mBC

January 11th 2020

HER2+ BC: Selection and Management of Neoadjuvant Therapy

January 11th 2020

Overview of Neoadjuvant Therapy in HER2+ Breast Cancer

January 11th 2020

Early-Stage HER2+ Breast Cancer: The ATEMPT Trial

January 11th 2020

Impact of the KATHERINE Trial on Early-Stage HER2+ BC

January 11th 2020

Adjuvant Strategies in Early-Stage HER2+ Breast Cancer

January 11th 2020

Evolving Landscape of HER2-Targeted Therapy in Breast Cancer

January 11th 2020

Dr. Backes on Financial Toxicity Considerations in Ovarian Cancer

January 10th 2020

Floor J. Backes, MD, discusses the consideration of financial toxicity when choosing a PARP inhibitor for a patient with ovarian cancer.

Dr. O'Malley on Remaining Questions in Ovarian Cancer

January 8th 2020

David O’Malley, MD, discusses remaining questions in the ovarian cancer field.

The Development of Genetic Testing in Ovarian Cancer

January 7th 2020

Leigha Senter, MS, LGC, discusses the development of genetic testing in ovarian cancer.

Dr. Moore on Treatment for Patients With Ovarian Cancer Who Develop Resistance to PARP Inhibitors

January 3rd 2020

Kathleen Moore, MD, director, Oklahoma TSET Phase I Program, and associate professor, Section of Gynecologic Oncology, Stephenson Cancer Center, discusses treatment for patients with ovarian cancer who progress on a PARP inhibitor.

Success Breeds a Need for Oncology Trials That Tackle Real-World Questions

December 30th 2019

Placing the results of a single trial in the context of real-world, everyday practice is increasingly difficult because of the number of available options and the absence of studies that directly compare individual strategies.

Outlining Advances Made in Ovarian Cancer in Oklahoma City

December 25th 2019

We traveled to Oklahoma City, Oklahoma, for a State of the Science Summit™ on Ovarian Cancer, which featured insights from the Stephenson Cancer Center faculty.